Oculus Innovative Sciences, Inc. Reports Revenues of $15.5 Million for Fiscal Year 2013, Product Revenue Up 23 Percent

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PETALUMA, Calif., June 13, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced financial results for the fourth quarter of fiscal year 2013, ended March 31, 2013. Total revenues were $3.3 million for the fourth quarter ended March 31, 2013, compared to $3.4 million for the same period in the prior year. Product revenues, including product licensing fees, were flat for the fourth quarter ended March 31, 2013, as compared to the same period in the prior year, with increases in Europe, China, India and Singapore offset by declines in the United States and Mexico. The flat quarterly revenue growth was the result of two factors: 1) the More Pharma transaction reduced Oculus' short-term revenue growth despite a 49% increase in unit volume sales, while improving operating profitability and long-term revenue growth prospects, and 2) the delayed seasonal purchasing in the ranch and farm animal market of the Vetericyn™ animal healthcare products due to late winter storms.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC